3 Undervalued Pharmaceuticals Stocks for Monday, June 16
Discover the top 3 undervalued Pharmaceuticals stocks for Monday, June 16 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Commentary & Analysis
5 Undervalued Pharmaceuticals Stocks for Thursday, May 15
Discover the top 5 undervalued Pharmaceuticals stocks for Thursday, May 15 based on AAII’s Stock Grades.Omar Beirat
3 Undervalued Pharmaceuticals Stocks for Wednesday, March 05
Discover the top 3 undervalued Pharmaceuticals stocks for Wednesday, March 05 based on AAII’s Stock Grades.Tudor Pop
3 Undervalued Pharmaceuticals Stocks for Monday, January 27
Discover the top 3 undervalued Pharmaceuticals stocks for Monday, January 27 based on AAII’s Stock Grades.Aneeqa Nadeem
Is Biostem Technologies Inc (BSEM) Stock a Good Investment?
Learn more about Biostem Technologies Inc's (BSEM) stock grades for Growth and Estimate Revisions and determine whether this Pharmaceuticals stock meets your investment needs.Jack Gilleland
Financial Summary
| Share Statistics | BSEM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $55.0 | $634.5 | 16% |
|
| Shares Out (Mil) | 17.3 | 44.5 | 28% |
|
| Institutional Ownership | 0.0% | 84.4% | 0% |
|
| Float (Mil) | 14.0 | 46.8 | 24% |
|
| Beta | na | 0.73 | na |
|
| Avg Daily Volume (000s) | 162 | 365 | 41% |
|
| Price Change (52-week) |
(69.9%) | 66.1% | 9% |
|
| Growth | BSEM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 139.7% | 6.7% | 99% |
|
| Net Income (5yr) | (10.5%) | (1.4%) | 28% |
|
| EPS (5yr) | 18.9% | 14.9% | 66 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 47.6% | (14.9%) | 93% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | ($1.950) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | (21.1%) | |
| Financials | BSEM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $91 | $276 | 25% |
|
| Net Income (TTM) (Mil) | ($28) | ($11) | 21% |
|
| EPS (TTM) | ($1.637) | ($0.700) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($6) | 24% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $62 | $309 | 19% |
|
| Valuation | BSEM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.00 | 2.88 | 50% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BSEM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 92.4% | 67.5% | 94% |
|
| Net Margin | (30.4%) | (2.3%) | 15% |
|
| ROA | (34.3%) | (22.5%) | 16% |
|
| ROE | (73.2%) | (19.8%) | 12% |
|
| Liabilities to Assets | 43.4% | 32.4% | 34% |
|
| F-Score | 4 | 3 | 34% |
|
BioStem Technologies, Inc. did not pass any screens on 8/13/2026.
